468 related articles for article (PubMed ID: 29307688)
1. Pathogenic roles of B lymphocytes in systemic sclerosis.
Yoshizaki A
Immunol Lett; 2018 Mar; 195():76-82. PubMed ID: 29307688
[TBL] [Abstract][Full Text] [Related]
2. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Takehara K; Tedder TF
Mol Immunol; 2004 Nov; 41(12):1123-33. PubMed ID: 15482848
[TBL] [Abstract][Full Text] [Related]
3. B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets.
Yoshizaki A
J Dermatol; 2016 Jan; 43(1):39-45. PubMed ID: 26782005
[TBL] [Abstract][Full Text] [Related]
4. [B cell abnormalities and therapeutic strategies in systemic sclerosis].
Yoshizaki A
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):197-206. PubMed ID: 27320935
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of systemic sclerosis: altered B cell function is the key linking systemic autoimmunity and tissue fibrosis.
Hasegawa M; Fujimoto M; Takehara K; Sato S
J Dermatol Sci; 2005 Jul; 39(1):1-7. PubMed ID: 15885984
[TBL] [Abstract][Full Text] [Related]
6. B cells in systemic sclerosis: a possible target for therapy.
Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
[TBL] [Abstract][Full Text] [Related]
7. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
Hasegawa M
J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
[TBL] [Abstract][Full Text] [Related]
8. Abnormal B lymphocyte activation and function in systemic sclerosis.
Yoshizaki A; Sato S
Ann Dermatol; 2015 Feb; 27(1):1-9. PubMed ID: 25673924
[TBL] [Abstract][Full Text] [Related]
9. B Lymphocyte signaling established by the CD19/CD22 loop regulates autoimmunity in the tight-skin mouse.
Asano N; Fujimoto M; Yazawa N; Shirasawa S; Hasegawa M; Okochi H; Tamaki K; Tedder TF; Sato S
Am J Pathol; 2004 Aug; 165(2):641-50. PubMed ID: 15277237
[TBL] [Abstract][Full Text] [Related]
10. Role of B cells in the pathogenesis of systemic sclerosis.
Sanges S; Guerrier T; Launay D; Lefèvre G; Labalette M; Forestier A; Sobanski V; Corli J; Hauspie C; Jendoubi M; Yakoub-Agha I; Hatron PY; Hachulla E; Dubucquoi S
Rev Med Interne; 2017 Feb; 38(2):113-124. PubMed ID: 27020403
[TBL] [Abstract][Full Text] [Related]
11. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
12. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis.
Hasegawa M; Hamaguchi Y; Yanaba K; Bouaziz JD; Uchida J; Fujimoto M; Matsushita T; Matsushita Y; Horikawa M; Komura K; Takehara K; Sato S; Tedder TF
Am J Pathol; 2006 Sep; 169(3):954-66. PubMed ID: 16936269
[TBL] [Abstract][Full Text] [Related]
13. B lymphocytes and systemic sclerosis.
Fujimoto M; Sato S
Curr Opin Rheumatol; 2005 Nov; 17(6):746-51. PubMed ID: 16224253
[TBL] [Abstract][Full Text] [Related]
14. Pathogenesis of systemic sclerosis-current concept and emerging treatments.
Furue M; Mitoma C; Mitoma H; Tsuji G; Chiba T; Nakahara T; Uchi H; Kadono T
Immunol Res; 2017 Aug; 65(4):790-797. PubMed ID: 28488090
[TBL] [Abstract][Full Text] [Related]
15. [B cell abnormalities and autoantibody production in systemic sclerosis].
Sato S
Nihon Rinsho Meneki Gakkai Kaishi; 2006 Apr; 29(2):73-84. PubMed ID: 16651705
[TBL] [Abstract][Full Text] [Related]
16. The immunobiology of systemic sclerosis.
Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
[TBL] [Abstract][Full Text] [Related]
17. Immunization with DNA topoisomerase I and Freund's complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling.
Yoshizaki A; Yanaba K; Ogawa A; Asano Y; Kadono T; Sato S
Arthritis Rheum; 2011 Nov; 63(11):3575-85. PubMed ID: 21792823
[TBL] [Abstract][Full Text] [Related]
18. B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis.
Numajiri H; Kuzumi A; Fukasawa T; Ebata S; Yoshizaki-Ogawa A; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Yoshizaki A; Sato S
Arthritis Rheumatol; 2021 Nov; 73(11):2086-2095. PubMed ID: 33955200
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
Noda S; Asano Y; Nishimura S; Taniguchi T; Fujiu K; Manabe I; Nakamura K; Yamashita T; Saigusa R; Akamata K; Takahashi T; Ichimura Y; Toyama T; Tsuruta D; Trojanowska M; Nagai R; Sato S
Nat Commun; 2014 Dec; 5():5797. PubMed ID: 25504335
[TBL] [Abstract][Full Text] [Related]
20. Early inflammatory players in cutanous fibrosis.
Raker V; Haub J; Stojanovic A; Cerwenka A; Schuppan D; Steinbrink K
J Dermatol Sci; 2017 Sep; 87(3):228-235. PubMed ID: 28655471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
